Skip to main content

Benitec Biopharma Inc.

BNTC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001808898

No open-market purchases or sales by Benitec Biopharma Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $463.9M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +1 vs. previous quarter
86
13F valueReported value at the end of Q2 2026
$463.9M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding BNTC, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BNTC at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Benitec Biopharma Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 29, 2025 (view filing)7:31 PM ETDec 23-296 daysMontanova Capital, LLC and 3 othersDirector, 10% OwnerPPurchaseCommon stock, par value $0.0001 per share+144.2K$13.20+$1.90M+8.5%1.85M after6 lots
Dec 22, 2025 (view filing)7:45 PM ETDec 18-224 daysMontanova Capital, LLC and 3 othersDirector, 10% OwnerPPurchaseCommon stock, par value $0.0001 per share+46.1K$11.68+$539.0K+2.6%1.83M after6 lots
Nov 10, 2025 (view filing)9:51 PM ETNov 73 daysMontanova Capital, LLC and 3 othersDirector, 10% OwnerPPurchaseCommon stock, par value $0.0001 per share+1.48M$13.50+$20.0M+437.9%1.82M after2 lots
Apr 2, 2025 (view filing)4:37 PM ETMar 312 daysMontanova Capital, LLC and 3 othersDirector, 10% OwnerPPurchaseCommon stock, par value $0.0001 per share+16.5K$12.83+$211.7K+1.6%1.07M after4 lots
Mar 28, 2025 (view filing)4:51 PM ETMar 262 daysMontanova Capital, LLC and 3 othersDirector, 10% OwnerPPurchaseCommon stock, par value $0.0001 per share+900.0K$13.00+$11.7M+539.7%1.07M after2 lots
Dec 26, 2024 (view filing)4:28 PM ETDec 23-243 daysMontanova Capital, LLC and 3 othersDirector, 10% OwnerPPurchaseCommon stock, par value $0.0001 per share+47.5K$11.09+$527.2K+5.2%960.6K after4 lots
Dec 5, 2024 (view filing)4:36 PM ETDec 32 daysMontanova Capital, LLC and 3 othersDirector, 10% OwnerPPurchaseCommon stock, par value $0.0001 per share+42.0K$9.60+$403.2K+4.6%955.1K after2 lots
Nov 21, 2024 (view filing)4:24 PM ETNov 19-202 daysMontanova Capital, LLC and 3 othersDirector, 10% OwnerPPurchaseCommon stock, par value $0.0001 per share+41.4K$10.05+$416.6K+4.6%950.3K after4 lots
Aug 14, 2023 (view filing)Aug 113 daysBuchi J KevinDirectorPPurchase+51.8K––+18,244.0%52.1K after
Aug 14, 2023 (view filing)Aug 113 daysBuchi J KevinDirectorPPurchase+51.8K–––51.8K afterDerivative

Top 10 13F holders, Q2 2026

The largest institutional positions in Benitec Biopharma Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 86 holders
Institutions holding BNTC in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Suvretta Capital Management, LLC11,548,351$154.5M3.25%00.0%Unchanged
Nantahala Capital Management, LLC2,976,742$39.8M1.21%+1,538,371+107.0%Added
Jupiter Topco LLC2,478,547$33.1M0.01%+2,478,547New
Franklin Resources Inc2,412,888$32.3M0.01%+34,729+1.5%Added
Adage Capital Partners GP, L.L.C.2,120,672$28.4M0.04%00.0%Unchanged
Ra Capital Management, L.P.1,850,000$24.8M0.22%00.0%Unchanged
BlackRock, Inc.1,407,138$18.8M0.00%+221,397+18.7%Added
Simplify Asset Management Inc.1,005,557$13.5M0.19%+443,315+78.8%Added
Vanguard Capital Management LLC954,533$12.8M0.00%+22,977+2.5%Added
Infinitum Asset Management, LLC923,006$12.3M1.26%00.0%Unchanged